Entera Bio Ltd.
ENTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001638097
No open-market purchases or sales by Entera Bio Ltd. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $19.0M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Entera Bio Ltd. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 9 | 12 | +3 |
| Shares | 2.83M | 2.57M | −261.6K (−9.2%) |
| Value | $3.28M | $2.17M | −$1.12M (−34.1%) |
New holders (5)
Institutions that held Entera Bio Ltd. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HRT Financial LP | 26,414 | $22.0K | 0.00% |
| HighTower Advisors, LLC | 11,830 | $10.0K | 0.00% |
| Advisor Group Holdings, Inc. | 750 | $633 | 0.00% |
| Citadel Advisors LLC | 32 | $27 | 0.00% |
| Simplex Trading, LLC | 99 | $0 | 0.00% |
Sold out (2)
Institutions that held Entera Bio Ltd. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Ra Capital Management, L.P. | 295,966 | $343.3K |
| JPMorgan Chase & Co | 1,868 | $2.00K |